CSIMarket
 
Bluejay Diagnostics Inc   (BJDX)
Other Ticker:  
 
 
Price: $0.8356 $0.04 4.424%
Day's High: $0.8739 Week Perf: 2.14 %
Day's Low: $ 0.78 30 Day Perf: 5.77 %
Volume (M): 48 52 Wk High: $ 11.14
Volume (M$): $ 40 52 Wk Avg: $2.29
Open: $0.78 52 Wk Low: $0.19



 Market Capitalization (Millions $) 1
 Shares Outstanding (Millions) 1
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -10
 Cash Flow (TTM) (Millions $) -14
 Capital Exp. (TTM) (Millions $) 2

Bluejay Diagnostics Inc
Bluejay Diagnostics Inc is a healthcare company that specializes in the development and production of innovative diagnostic solutions. The company focuses on creating a range of diagnostic products, including rapid diagnostic tests, point-of-care devices, and lab-based testing solutions for various medical conditions. Bluejay Diagnostics Inc aims to improve patient outcomes by delivering accurate and timely diagnostic results while also providing convenience and ease of use for healthcare professionals.


   Company Address: 360 Massachusetts Avenue Acton 1720 MA
   Company Phone Number: 327-7078   Stock Exchange / Ticker: NASDAQ BJDX
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Financing Agreement

Bluejay Diagnostics Sets Offering Price at $1.30 per Share to Raise $3.5 Million, Amidst Steady Leverage Ratio Improvement

Published Thu, Dec 28 2023 1:00 PM UTC

Bluejay Diagnostics, Inc. (NASDAQ: BJDX) recently announced the pricing of a public offering of its common stock and warrants, aiming to raise $3.5 million. The medical technology company, known for developing rapid diagnostics on its Symphony platform, aims to improve patient outcomes in critical care settings. The offering involves 2,692,308 shares of common stock (or pre-...

Product Service News

Bluejay Diagnostics' Revolutionary Symphony IL-6 Moves Closer to Transforming Sepsis Diagnosis and Patient Care

Published Wed, Dec 27 2023 2:00 PM UTC

Bluejay Diagnostics, Inc. Announces Initiation of Multicenter Clinical Study Evaluating Symphony IL-6 in Sepsis Patients (SYMON Study)Bluejay Diagnostics, a leading biotechnology company, has recently made an exciting announcement regarding the initiation of a multicenter clinical study called SYMON, which aims to evaluate the effectiveness of their innovative diagnostic too...

Bluejay Diagnostics Inc

Breakthrough News: Bluejay Diagnostics Inc. Rockets to Success in Booming Medical Equipment & Supplies Market with Spectacular Q3 2023 Earnings!

Bluejay Diagnostics Inc, a company in the Medical Equipment & Supplies industry, recently reported an operating deficit of $-2.341233 million for the most recent fiscal period. While this may initially seem concerning, it is actually a significant improvement from the operating deficit of $-2.810178 million reported during the same period a year ago. This positive trend has sparked optimism among analysts regarding the company's future prospects.
One promising revelation is that the deficit has further receded to $-2.298 million from $-2.960 million in the third quarter of 2022. This steady improvement indicates that Bluejay Diagnostics Inc is moving in the right direction and may potentially emerge as a successful leader in the industry.

Bluejay Diagnostics Inc

Bluejay Diagnostics Inc Witnesses Stagnant Revenue in Q2 2023 Despite Surging Deficit: Implications for Shareholders


Introduction
The stock market never fails to surprise investors, and one such recent development is the fiscal second-quarter performance of Bluejay Diagnostics Inc. In their most recent financial report, the company's deficit per share saw a significant jump from the previous year, while their revenue remained stagnant. This article aims to explore these interesting facts and shed light on the potential implications for shareholders.
Exploring the Deficit Situation
Bluejay Diagnostics Inc experienced a substantial increase in their deficit per share for the fiscal second quarter of 2023. The figure rose to $-2.75 per share, which is a stark contrast to the $-0.10 reported the previous year. Moreover, the company's deficit grew from $-0.12 per share in the previous reporting period. This financial downturn raises concerns about the company's financial health.

Bluejay Diagnostics Inc

Bluejay Diagnostics Inc: The Diamond in the Rough Making Waves in the Medical Equipment & Supplies Market

Investors may want to take note of Bluejay Diagnostics Inc's recent operating shortfall for the first quarter of 2023. Despite trailing behind larger companies in the Medical Equipment & Supplies industry, the ascending corporation is quickly catching the attention of savvy investors.
Bluejay Diagnostics Inc reported an operating shortfall of $-2.679572 million for the first quarter of 2023. While the respective revenue has not been disclosed yet, we can compare this to their business achievement through the first quarter of 2022, where they realized an operating shortfall of $-2.068261 million. It's evident that the corporation is experiencing some setbacks in their quest for a prosperous business strategy, with the deficit extending to $-2.540 million for the first quarter of 2023.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com